Search results
Showing 421 to 435 of 438 results for cardiovascular disease
In the Labonte model, health behaviours are actions individuals take that affect their health positively or negatively such as smoking, substance abuse or physical activity.
In the Labonte model, physiological impacts refer to the direct effects on the body’s systems and functions due to factors such as stress, lifestyle choices, and environmental conditions.
The Marmot Review summarised the importance the impact of addressing inequalities in health in later life and investing in the early years to preventing ill health later in life.
In virtual wards, people can receive virtual and technology-assisted treatment, assessment, and monitoring.
NICE describes how weight loss drug tirzepatide will be rolled out
The medication will initially be offered only to those people with the highest clinical needs.
NICE recommended weight-loss drug to be made available in specialist NHS services
Thousands of people will soon be able to be prescribed a drug to help them lose weight as part of their treatment in an NHS specialist weight management service.
NICE's Early Value Assessment for Medtech: panning for nuggets of innovation gold
Early Value Assessment for Medtech and how it will offer a rapid assessment of digital products, devices and diagnostics for clinical effectiveness and value for money.
Dr Sam Roberts, chief executive of NICE, celebrates the NHS on its 75th anniversary. She discusses how NICE has supported the NHS with its recent achievements. She also highlights how NICE is evolving; through driving value-based healthcare to support the NHS as it adapts to meet current challenges.
New treatment for cardiovascular disease could benefit millions
Up to 2.1 million people with cardiovascular disease (CVD) could benefit from a new cholesterol target outlined in NICE guidance for the first time.
Hundreds of thousands set to benefit from new treatment to prevent heart attacks and strokes
NICE has published final draft guidance which recommends icosapent ethyl for reducing the risk of heart attacks and strokes in adults who have raised blood fats.
New treatment option for adults with obesity and non-diabetic hyperglycaemia
All eligibility criteria must be met for Liraglutide to be offered.
Updated menopause guidance includes discussion aid to support conversations about HRT
Our updated guideline on menopause emphasises the importance of an individualised approach and shared decision-making when making choices about treatment for symptoms.
More people are benefitting from NICE-recommended statins to reduce heart attacks and strokes
Around 5.3 million people in England were given a NICE-recommended statin or ezetimibe by their GP to help reduce their cholesterol during 2023/24, the largest number on record and almost 900,000 more than in 2022/23.
Consultation on NHS England proposals for a phased launch of obesity injection
Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins.
Keep the size of your waist to less than half of your height, NICE recommends
People are being encouraged to keep their waist measurement to less than half their height to reduce the risk of potential health problems.